# A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

> **NCT00612209** · PHASE1 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 51 (actual)

## Conditions studied

- Cancer, Advanced Solid Tumors

## Interventions

- **DRUG:** ARQ 197

## Key facts

- **NCT ID:** NCT00612209
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-01
- **Final completion:** 2010-02
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2012-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612209, "A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00612209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*